Liquid Biopsy clinical trials at UCSF
1 research study open to eligible people
Showing trials for
Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors
open to eligible people ages 18-80
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 for liquid biopsy in subjects with suspected Glioblastoma brain tumors
San Francisco, California and other locations
Our lead scientists for Liquid Biopsy research studies include John de Groot, M.D..
Last updated: